



## News Release

**Media Contact:**

Dennis Fortier  
Phone: (949) 838-0154 x388  
Email: dfortier@mccare.com

### **LEADING COGNITIVE RESEARCHERS NAMED TO SCIENTIFIC ADVISORY BOARD AT MEDICAL CARE CORPORATION**

IRVINE, CA., March 04, 2008, Medical Care Corporation (MCC), the leading provider of high accuracy memory assessment technology, announced today the formal assembly of its Scientific Advisory Board. The board will help the company provide physicians and researchers with improved tools to effectively detect, diagnose, and manage diseases that impair memory. The scientific advisory board is chaired by David S. Geldmacher, M.D. and includes Jeffrey L. Cummings, M.D., Michael Rafii, M.D., Ph.D., Marwan Sabbagh, M.D. and Frederick Schmitt, Ph.D.

The board has strong representation from the disciplines of Neurology, Psychiatry, and Neuropsychology and the members include individuals with extensive experience in the federally-funded Alzheimer's Disease Research Centers program and the Alzheimer's Disease Cooperative Study consortium, as well as from privately-funded clinical research organizations.

"This is an impressive group of scientists," said Medical Care Corporation CEO Dennis Fortier. "Their ongoing contributions to what the world knows about fighting Alzheimer's disease and related causes of memory loss cannot be underestimated. We are honored to have such a capable and highly respected group of advisors to support our scientific efforts."

There are more than 5 million Americans currently diagnosed with Alzheimer's disease and another estimated 5 million at risk for developing the disease within five years. Fortier noted that earlier detection and timely intervention have become critically important steps along the path to improving care for an aging society.

Advisory Board Chairman, Dr. David Geldmacher said, "Without a significant improvement in detecting Alzheimer's disease risks among the baby boomer generation, demographic trends will make this an overwhelming public health and health economics problem over the next several decades. It is the early stage, undiagnosed population that can most benefit from timely detection and appropriate intervention. Technologies like those developed by MCC can provide physicians with effective tools to combat the growing problem of Alzheimer's disease by enabling earlier detection and treatment."

Members of the Medical Care Corporation Scientific Advisory Board include:

**David S. Geldmacher, MD**, is the Harrison Distinguished Teaching Associate Professor of Neurology at the University of Virginia Health System in Charlottesville, VA, where he also serves as the Medical Director of the Memory Disorders Clinic.

**Jeffrey L. Cummings, M.D.** is the director of the Alzheimer's Disease Center at the University of California, Los Angeles and the Augustus S. Rose Professor of Neurology and Professor of Psychiatry and Biobehavioral Sciences at UCLA. In addition, he is a member of the Alzheimer's Disease Cooperative Study and the Neuroprotection in Parkinson's Disease oversight committee.

**Michael Rafii**, MD, Ph.D is a senior Dementia and Cognitive Neurology fellow in the Department of Neurosciences at the University of California, San Diego. He specializes in the molecular mechanisms of neurodegenerative diseases including Alzheimer's disease.

**Marwan Sabbagh**, M.D. is the founding director of Cleo Roberts Center for Clinical Research at Sun Health Research Institute, Sun City, AZ. He is also the Associate Director of the Arizona Alzheimer's Disease Core Center, a clinical instructor in the Sun Health/St. Joseph's Hospitals Geriatric Fellowship Program, clinical assistant professor of neurosciences at the University of California, San Diego and a visiting scientist in the Department of Neurology at Mayo Clinic Scottsdale.

**Frederick Schmitt**, Ph.D. is a professor of Neurology at University of Kentucky College of Medicine with joint appointments in the departments of Psychiatry, Psychology, and Behavioral Science. He serves as a co-director of the Memory Disorders Clinic and as co-director of the Biostatistics and Data Management Core at the Alzheimer's Disease Research Center, University of Kentucky Medical Center. He also holds an appointment as a Center Associate in the Sanders-Brown Center on Aging.

### **About Medical Care Corporation**

Medical Care Corporation is a neuroinformatics company specializing in the development of analytical methods to precisely measure cognition. The company's MCI Screen is 97.3% accurate in distinguishing a pre-dementia stage called mild cognitive impairment (MCI) from normal aging. The company is also a leader in communicating the value of prevention and early detection to patients and caregivers through its website and educational materials. Additional information about the company is available at two websites: For Health Care Providers: [www.mccare.com](http://www.mccare.com); For Patients and Caregivers: [www.PreventAD.com](http://www.PreventAD.com).